Professor Bosnic-Anticevich is a medical researcher and respiratory pharmacist internationally recognised as an expert in respiratory medicines use. She is founder and Head of the Quality Use of Respiratory Medicines Group at the Woolcock Institute of Medical Research and The University of Sydney.

Sinthia’s research has led to the development of the “gold standards” in the use of inhalers, impacting on national and international treatment guidelines for asthma, COPD and allergic rhinitis. Her research with different patient populations, health care professionals and health care settings is key to our understanding of how to optimise the use of respiratory medicines for improved health outcomes.

In collaboration with her network of multidisciplinary, global collaborators, Sinthia has over 200 research publications, has been awarded over $20m in research funding, and has a reputation for her innovative and a pragmatic approach to solving health care problems associated with medicines use. She is regularly invited to present both nationally and internationally to clinicians across a range of health disciplines on the topic of respiratory medicines use.

Sinthia is President of the Respiratory Effectiveness Group (REG), Executive Director of ARIA (Allergic Rhinitis in Asthma), Chair of Pharmacy ARIA, and Chair of the Primary Care SIG of the Thoracic Society of Australia and New Zealand. She is on the editorial board of several prestigious international respiratory journals, including the European Respiratory, European Respiratory Journal Monograph and The Medical Republic (Australia’s most widely circulated GP newsletter). She sits on several global pharmaceutical industry advisory boards associated with the use of medicines in the management of respiratory diseases.

Sinthia continues to practice pharmacy and mentor clinicians and research students in achieving their career aspirations.

View Sinthia's academic profile at Macquarie University